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Background. 18F-fluorodeoxyglucose (FDG) PET plays an important role in the detection of
cardiac involvement sarcoidosis (CS). However, diffuse left ventricle (LV) wall uptake some-
times makes it difficult to distinguish between positive uptake and physiological uptake. The
aims of this study were to evaluate the effects of 18-h fasting with low-carbohydrate diet (LCD)
vs a minimum of 6-h fasting preparations on diffuse LV FDG uptake and free fatty acid (FFA)
levels in patients with suspected CS.
Methods. Eighty-two patients with suspected CS were divided into 2 preparation protocols:
one with a minimum 6-h fast without LCD preparation (group A, n 5 58) and the other with a
minimum 18-h fast with LCD preparation (group B, n 5 24). All patients also received
intravenous unfractionated heparin (UFH; 50 IU/kg) before the injection of FDG.
Results. Group A showed a higher percentage of diffuse LV uptake than did group B (27.6 vs
0.0%, P 5 .0041). Group B showed higher FFA levels (1159.1 ± 393.0, 650.5 ± 310.9 lEq/L,
P < .0001) than did groupA. Patients with diffuse LV uptake (n 5 16) showed lower FFA levels than
did other patients (n 5 66) (432.1 ± 296.1, 888.4 ± 381.4 lEq/L, P < .0001). UFH administration
significantly increased FFAs in both groups, even in the patients with diffuse LV FDG uptake.
Conclusions. The 18-h fast with LCD preparation significantly reduced diffuse LV uptake and
increased FFA levels. In particular, the FFA level was significantly lower in patients with LV diffuse
uptake than in patients without LVdiffuse uptake. Acutely increasing plasmaFFA through the use of
UFH may not have a significant role in reducing physiological LV FDG uptake. (J Nucl Cardiol
2016;23:244–52.)
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18F-fluorodeoxyglucose (FDG) positron emission
tomography (PET) plays an important role in the
detection of active inflammatory lesions in cardiac
involvement sarcoidosis (CS).1-4 Recently, the Heart
Rhythm Society (HRS) issued a consensus statement on
the diagnosis and management of arrhythmias associated
with CS.5 In this statement, FDG PET was recom-
mended for advanced cardiac imaging in CS diagnosis.
A FDG PET preparation protocol and image interpre-
tation should therefore be improved and standardized.
The Japanese Society of Nuclear Cardiology (JSNC) has
also issued FDG PET imaging guidelines for diagnosis
CS.1 The positive uptake pattern is defined using visual
assessment in HRS and JSNC guidelines. By adding a
quantitative parameter over the standard visual analysis,
FDG PET may improve the ability to diagnose patients
with CS. For the evaluation of FDG uptake, volume-
based parameters were proposed to estimate disease
progression in the assessment of malignant tumors.6,7
Ahmadian et al also applied FDG volume measurement
for patients with cardiac sarcoidosis.8
Sarcoidosis is a systemic granulomatous disease
with unknown etiology.9 Manifestation of sarcoidosis
varies from an asymptomatic state to a progressive
disease, and CS has the greatest life-threatening poten-
tial in sarcoidosis patients.10 Therefore, the precise
diagnosis of CS is important to sarcoidosis patients. The
heart uses a variety of energy sources such as free fatty
acids (FFA), glucose, lactate, and ketone bodies.11,12
FDG is an analog of glucose. Theoretically, glucose use
during a fasting state is limited but diffuse left ventricle
(LV) wall FDG uptake is sometimes reported even under
fasting conditions.2,13 In addition, FDG uptake in the
entire LV wall is generally considered to be physiolog-
ically normal.1 This physiological uptake makes it
difficult to distinguish between active inflammation
and physiological distribution.1,14 Myocardial FDG
uptake is known to be correlated inversely with serum
FFA concentration but not with serum insulin concen-
tration.15-17 Several recent studies have focused on
reducing physiological FDG uptake through such mea-
sures as performing extended fasting, following a
particular regime (a low-carbohydrate diet or a high-
fat diet), or receiving unfractionated heparin (UFH), and
they have examined the usefulness of provoking a shift
from glucose metabolism to FFA metabolism.1,2,18-20
However, there have been limited data to evaluate the
association between certain details of FFA level and
diffuse LV FDG uptake under a longer fasting period
and LCD in patients with suspected CS. In addition, the
effect of UFH in reducing diffuse LV FDG uptake has
not been established. The aims of this study were to
examine the effect of the preparations on diffuse LV
FDG uptake and to evaluate the association between
diffuse LV FDG uptake and FFA levels before and after
UFH injection. We also tried to evaluate the cardiac
FDG uptake volume and compare that evaluation to the
visual assessment.
MATERIALS AND METHODS
Subjects and Study Design
This study protocol was approved by the ethics committee
of the Hokkaido University Graduate School of Medicine.
Written informed consent was obtained prior to the study.
Patients with suspected CS who underwent FDG PET or PET/
CT from February 2002 to June 2013 were prospectively
included in the current study. Patients were excluded if they
lacked blood samples or the latter were insufficient for the
purpose of measurements. Patients with a history of coronary
artery disease (CAD) were also excluded from this study. We
also excluded patients with any other known heart disease such
as myocarditis, valvular heart disease, or other cardiomy-
opathies as identified by echocardiography. Out of 95 patients,
13 were excluded because they lacked blood samples or a large
enough blood sample for detailed measurements (n = 12), or
because they had hypoglycemia before the FDG PET/CT scan
(n = 1).
Patient Group
The final study population comprised 82 patients (22 men
and 60 women), ranging in age from 22 to 76 years
(54.1 ± 15.8 years). Patients were sequentially divided into 2
groups based on their FDG preparation protocol. Between
See related editorial, pp. 253–255
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February 2002 and April 2010, 58 patients underwent at least
6 h’ fasting without LCD (group A). After May 2010, 24
patients underwent over 18 h’ fasting with LCD (group B).
The patients in group B ate a LCD with less than 5 g of
carbohydrate per meal along with a boiled egg, tofu with
bonnet flakes, and grilled chicken breast with stir-fried
vegetables.2 Diabetic medications were skipped beginning in
the morning. Long-acting insulin was skipped beginning the
previous night. Patients were not randomly divided between
the 2 protocols. Rather, they were placed into one of the two
protocols according to the timeframe of the study. Group A
(the 6 h fast group) was formed prior to May 2010; group B
(the 18 h fast group) was formed after May 2010. In group A,
we further divided the patients into two groups based on FDG
findings: positive for diffuse LV FDG uptake (group A1) and
negative for diffuse LV FDG uptake (group A2).
Heparin Injection and Blood Sampling
Prior to FDG PET imaging, we checked for contraindi-
cation of heparin use such as active bleeding, bleeding risk, or
a history of heparin-induced thrombocytopenia. None of the
patients in this study population had contraindication for
heparin use. All patients received intravenous unfractionated
heparin (UFH; 50 IU/kg, Mochida, Tokyo) 15 min prior to
FDG injection.14,21 Before and 15 min after UFH administra-
tion, blood samples were obtained to measure immunoreactive
insulin (IRI) and FFA. Fasting plasma glucose (FPG) level was
also measured before FDG injection (Figure 1).
FDG PET or PET/CT Imaging
PET data acquisition was performed using a Siemens
ECAT Exact 47 or Siemens ECAT Exact HR ? scanner
(Siemens/CTI, Knoxville, TN, USA) (n = 50). PET/CT imag-
ing was performed using a Biograph 64 TruePoint with TrueV
(Siemens Japan, Tokyo) (n = 32). Transmission scanning for
PET or a low-dose CT for PET/CT was performed for
attenuation correction. Sixty minutes after FDG administra-
tion, a static FDG scan was performed.1 All scans were
performed using whole-body imaging.
FDG PET or PET/CT Imaging Analysis
At first, LV FDG myocardial uptake was evaluated
visually. Definite FDG uptake in the entire LV wall higher than
liver uptake was defined as diffuse LV FDG uptake based on
JSNC guidelines.1 Two nuclear medicine physicians blinded to
clinical and other test data independently evaluated the LV
myocardial FDG images.
We investigated the glucose metabolic status of the cardiac
lesions using maximal standard uptake value (SUVmax) and
cardiac metabolic volume (CMV). SUVmax was measured using
a volume of interest inserted on the fused axial image encom-
passing the entire heart, and reviewed to ensure that adjacent non-
cardiac FDG-avid structures were excluded. To calculate the
SUVmax of the blood pool, a region of interest (ROI) was drawn
around the left atrial lumen.22 For the volume-based assessment,
the whole process was done using dedicated software.7 The
algorithm required human interaction in the first step to put a 150-
mm spherical volume of interest (VOI) in the right lobe of the
liver. The subsequent processes were automated. The within-VOI
mean and standard deviation (SD) were used to determine a
threshold value as follows: threshold = mean ? 3 9 SD.23 An
experienced nuclear medicine physician thoroughly reviewed the
PET images and selected the FDG-avid areas in the LV region. In
cases in which LV uptake and uptake in adjacent structures (such
as lymph node) overlapped, the overlapwas carefully adjusted for
manually. The nuclear physician was blinded to the clinical
information and outcomes to avoid possible bias in software
operation. Two patients were excluded because of multiple liver
uptakes due to sarcoidosis.
Statistical Analyses
Data are expressed as mean ± standard deviation (SD),
and a P value of less than .05 is considered statistically
significant. For intra-group comparisons, Wilcoxon signed-
rank tests were applied to compare differences in the blood
samples between the patients in the 6-h fasting group and those
in the 18-h fasting group. Fisher’s exact test was used to
compare discrete data as appropriate. Statistical calculations
were carried out using statistical software (JMP version 10,
SAS Institute, Cary, NC, USA).
Figure 1. FDG PET data acquisition protocol. Group A (n = 58): minimum 6 h’ fasting before
FDG PET studies. Group B (n = 24): minimum 18 h’ fasting with low-carbohydrate diet. Both
groups had unfractionated heparin (UFH) administration 15 min prior to FDG injection. Scans were
performed at 60 min after the administration of FDG. Blood samples were obtained before and
15 min after UFH administration to measure immunoreactive insulin (IRI) and free fatty acids
(FFA). Fasting plasma glucose (FPG) level was measured before UFH injection.
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RESULTS
Patient Characteristics
Ninety-four patients did not have any issues under
long fasting preparation and heparin use. One patient
with over 18 h’ fasting experienced hypoglycemia
before FDG administration and this patient did not
undergo FDG PET study.
Between the two groups, there were no significant
differences in baseline characteristics including sex, age,
frequency of the patients who met the Japanese Ministry
of Health and Welfare criteria (JMHW),24 left ventric-
ular ejection fraction (LVEF), rate of focal uptake, and
steroid use (Table 1).
FDG PET or PET/CT Findings
There were no discordant findings between the two
observers. In group A, 16 patients (27.6%) showed
diffuse LV uptake (Figure 2A). On the other hand, no
patients (0.0%) in group B showed diffuse LV uptake
(Figure 2B). Therefore, group A showed high frequen-
cies of diffuse LV FDG uptake compared to group B
(P = .0041) (Table 2). The mean ± SD values of the
cardiac lesion and LV blood pool SUVmax were
1.9 ± 0.4 and 4.4 ± 2.1, for group A, and 2.0 ± 0.5
and 5.0 ± 3.1 for group B, respectively. There were no
significant differences between group A and group B.
There was also no significant correlation between FFA
and SUVmax of the blood pool (r = 0.027, P = .84 for
group A; r = 0.059, P = .78 for group B). The thresh-
old of liver uptake during PET was significantly lower
than it was for PET/CT (2.28 ± 0.53 vs 3.02 ± 0.64,
P\ .0001). The CMV was significantly larger in
patients with diffuse uptake than in patients without
diffuse uptake (PET: 211.1 ± 123.8 vs
56.1 ± 100.0 mL, P\ .0001; PET/CT: 128.8 ± 77.0 vs
9.2 ± 16.6 mL, P = .004) (Figure 3).
Blood Sample Data Before UFH
Administration
There were no significant differences in the insulin
levels of the two groups before UFH administration
(Table 3). Group B showed lower FPG (84.3 ± 11.1 vs 93.3
± 15.2 mg/dL,P = 0.001) andhigherFFA(1159.1 ± 393.0
vs 650.5 ± 310.9 lEq/L, P\ .0001) than did group A.
In addition, in group A, patients of group A1 with
diffuse LV FDG uptake showed significantly lower FFA
levels than did patients in group A2 without diffuse LV
FDG uptake before UFH injection (432.1 ± 296.1 vs
733.7 ± 276.8 lEq/L, P = .0023) (Figure 4).
Blood Sample Data After UFH
Administration
UFH administration significantly increased FFA in
both groups (P\ .0001). There were no significant differ-
ences in FFA levels for group A and those for group B
15 min after UFH injection (P = .52). In addition, with
regard to FFA levels 15 min after administration of UFH,
therewas no significant differencebetween levels for group
A1 and those for group A2 (1804.2 ± 739.7 vs
2110.8 ± 691.5 lEq/L, P = .26). Patients with diffuse
LVFDGuptake (groupA1) alsohad significantly increased
plasma FFA after UFH (P\ .0001) (Table 4).
DISCUSSION
The minimum 18-h fasting with LCD preparation
reduced FPG, increased FFA before UFH administra-
tion, and led to significantly suppressed diffuse LV FDG
uptake, according to not only visual evaluation but also
volume-based analysis, in comparison with results of
shorter fasting without LCD protocol. UFH administra-
tion led to increases in FFA levels; however, the FFA
levels after UFH administration might not play a
significant role in reducing diffuse LV FDG uptake.
Table 1. Patient characteristics
Group A (n 5 58) Group B (n 5 24) P value
Sex (male) 16 (27.6%) 6 (25.0%) 1.00
Age (years old) 53.0 ± 16.2 56.7 ± 14.6 .42
Meets JMHW criteria 18 (31.0%) 12 (50.0%) .11
Fasting time Not available 20.6 ± 1.3 h
Rate of focal uptake 41.4 (%) 54.2 (%) .29
Diabetes 2 (3.4%) 2 (8.3%) .58
LVEF 64.8 ± 12.9 66.7 ± 11.8 .56
Steroid therapy before PET scan 6 (10.3%) 3 (12.5%) .72
Group A: patients with minimum 6 h fasting; Group B: patients with minimum 18 h fasting and LCD preparation
JMHW, Japanese Ministry of Health and Welfare; LVEF, left ventricular ejection fraction estimated by echography
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FDG is an analog of glucose and FDG PET is
known to be useful for detecting inflammatory lesions.
Sarcoidosis lesions include inflammatory cell infiltration
by such things as lymphocytes and macrophages, which
utilize glucose for their energy source. FDG PET can
therefore be used to identify active sarcoidosis lesions.2
However, diffuse FDG uptake in the entire LV wall is
generally considered to be physiologically normal.1 In
the current study, the association between fasting
conditions and diffuse LV FDG uptake was significant.
Minimum 18-h fasting with LCD preparation led to
significantly suppressed diffuse LV FDG uptake com-
pared to results with the shorter fasting protocol. These
data may imply the importance of a gradual myocardial
metabolic shift from glucose use to fatty acid use in
fasting FDG imaging. The myocardium could derive
energy from a variety of sources such as FFA, glucose,
lactate, and ketone bodies.11 Several factors were known
to affect the utilization of an individual substrate,
including the plasma insulin concentration, availability
of alternative substrates, and myocardial blood flow
supply.25 The heart preferentially utilizes substrates that
yield energy from FFA and lactate, while glycolysis
normally produces only about 30% of substrates for the
citric acid cycle.26 In particular, the heart prefers to use
FFA for energy production, and under these conditions,
myocardial glucose uptake is low with fasting.15 In the
absence of dietary glucose intake and carbohydrate
intake due to prolonged fasting, the myocardium phys-
iologically adapts and makes a metabolic shift from
glucose use to fatty acid use. Under the long fasting
condition, glucose production and glucose oxidation
should be decreased. In contrast, FFA is mobilized from
adipose tissue and the increased FFA becomes an
alternative fuel in the myocardium.27 Wisneski et al
demonstrated the presence of a significant inverse
correlation between the arterial FFA level and myocar-
dial glucose uptake in normal healthy subjects.28
Specifically, after a carbohydrate meal, FFA uptake
and oxidation decrease, and glucose and lactate extrac-
tion increase.29 It has been suggested that this shift in
fuel preference is caused by the changes in substrate and
leads to the suppression of physiological glucose
metabolism. In fact, the current data showed higher
plasma FFA levels in the group of patients undergoing
long fasting with LCD. This increasing FFA use may be
significantly reduced by cardiac glucose metabolism.
Thus, long fasting with LCD preparation significantly
reduces physiological FDG uptake. In addition, even
with shorter fasting, some patients in the current study
Figure 2. Representative cases. Figure (A-D) shows a 73-year-old man with diffuse LV FDG
uptake, who was instructed to fast for a minimum of 6 h and whose FPG and FFA levels were
95 mg/dL and 464 lEq/L at baseline. Cardiac metabolic volume was estimated as 166.4 mL. There
are multiple abnormal uptakes in mediastinal and hilar lymph nodes. Figure (E-H) shows a 25-year-
old woman without diffuse LV FDG uptake, who had over 18 h’ fasting with a low-carbohydrate
diet. Her FPG and FFA levels were 76 mg/dL and 1924 lEq/L at baseline. FDG PET/CT shows
focal basal anterior wall uptake. Cardiac metabolic volume was estimated to be 8.3 mL. There are
multiple lung uptakes and multiple lymph node uptakes in supraclavicular, mediastinal, hilar, and
abdominal regions. MIP = maximum intensity projection.
Table 2. Prevalence of diffuse LV FDG uptake
Group A Group B
Diffuse LV FDG uptake (?) 16 (27.6%)* 0 (0.0%)
Diffuse LV FDG uptake (-) 42 (72.4%) 24 (100.0%)
Total 58 24
Group A: patients with minimum 6 h fasting without LCD
preparation. Group B: patients with minimum 18 h fasting
with LCD
LV, left ventricle; LCD, low-carbohydrate diet
*Group A showed high frequencies of diffuse LV FDG uptake
when compared to group B (P = .0041)
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showed significantly reduced physiological myocardial
FDG uptake. These patients also showed significantly
higher plasma FFA levels than did patients with diffuse
LV FDG uptake. This result may indicate the impor-
tance of increasing plasma FFA levels for fasting
cardiac FDG PET imaging or of measuring plasma
FFA before the fasting FDG PET study.
Langah et al reported the effects of 18-h fasting
preparation on the suppression of myocardial physio-
logical FDG uptake.13 They indicated that the frequency
of LV FDG uptake under prolonged fasting was signif-
icantly lower than under the short fasting protocol. In
their report, only one of the 10 patients (10.0%) had a
diffuse pattern. Morooka et al also reported the impor-
tance of prolonged fasting for evaluating active
inflammatory lesions in cardiac sarcoidosis.30 In their
study, healthy volunteers who fasted for 18 h showed
reduced physiological LV FDG uptake in comparison
with healthy volunteers who underwent 12 h of fasting
with heparin administration. In addition, they suggested
that the FFA level before UFH injection may be the
important factor in inhibiting physiological LV FDG
uptake. Physiological uptake was likely to be efficiently
inhibited when the FFA level was more than 760 lEq/L.
Our current data agree with their previous study. In this
study, we applied the longer fasting protocol to CS
patients and showed the usefulness of this preparation
for eliminating diffuse LV FDG uptake in clinical
settings. Thus, the current study added further insights to
those of previous studies by Langah et al13 and Morooka
et al.30
In the current study, the 18-h fasting group also
followed LCD. LCD also has an impact on myocardial
metabolism and may contribute to reducing physiolog-
ical FDG uptake.31 Kobayashi et al reported the
usefulness of LCD in suppressing myocardial
Figure 3. Comparison of cardiac metabolic volume. The cardiac metabolic volume in patients with
diffuse uptake was significantly larger than it was in patients without diffuse uptake (194.6 ± 118.5
vs 35.9 ± 79.3 mL, P\ .0001). The trend was similar for analysis by PET (211.1 ± 123.8 vs
56.1 ± 100.0 mL, P\ .0001) or by PET/CT (128.8 ± 77.0 vs 9.2 ± 16.6 mL, P\ .0001).
Table 3. Blood sample data
Pre UFH injection Post UFH injection
FPG (mg/dL) IRI (lU/mL) FFA (lEq/L) IRI (lU/mL) FFA (lEq/L)
Group A 93.3 ± 15.2 3.69 ± 2.93 650.5 ± 310.9 4.47 ± 2.38 2026.2 ± 712.1*
Group B 84.3 ± 11.1 3.16 ± 3.41 1159.1 ± 393.0 2.88 ± 3.67 2115.5 ± 531.3*
P value .0010 .099 \.0001 \.0001 .52
Group A: patients with minimum 6 h fasting. Group B: patients with minimum 18 h fasting and LCD preparation
UFH, unfractionated heparin; FPG, fasting plasma glucose; IRI, immunoreactive insulin; FFA, free fatty acid; LCD, low-carbohydrate
diet
*P\ .0001 vs before UFH administration
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physiological FDG uptake in healthy subjects.22 Kumar
et al reported that both restricted diet and duration of
fasting play an important role in determining the pattern
and suppression of myocardial FDG uptake.32 LCD may
have played a role in reducing the physiological LV
FDG uptake in the present study; however, since we did
not apply LCD to the shorter fasting group, we are not
able to conclude which factor played a more significant
role in the current study. Further study examining the
effects of LCD on myocardial physiological FDG uptake
under various fasting conditions should be conducted in
the future.
UFH activates lipoprotein lipase, enhances plasma
lipolytic activity, and increases FFA levels.33,34 There-
fore, UFH has been expected to reduce physiological LV
FDG uptake. In this regard, our group applied UFH for
fasting cardiac FDG PET studies in CS.14,21 However,
the full effects of heparin in reducing physiological LV
FDG uptake have not been established.1 In the current
study, UFH increased plasma FFA levels in both group
A and group B. In addition, in the short-fast group, the
difference in FFA levels after 15 min of UFH admin-
istration between patients with diffuse LV uptake and
those without diffuse LV uptake was not significant. The
current data agree with those of previous reports
indicating that patients with increased FFA responded
to UFH.14,35 Moreover, the present data may imply that
acutely increasing plasma FFA by UFH may not have a
significant role in reducing physiological LV FDG
uptake. A recent study by Gormsen et al reported that
heparin loading did not reduce myocardial FDG
uptake.36 Our data agree with previous data and also
may imply the importance of longer fasting with LCD
rather than heparin administration. However, the effects
of heparin should also be evaluated in future studies.
Distribution of FDG uptake might change in
patients with diabetes who use insulin or oral antidia-
betic drugs.37 There were four diabetic patients in this
study. Two of them were in group A and the other two
were in group B. Their FPG levels were lower than
114 mg/dL, and their uptake patterns were not diffuse. If
their results were excluded, the conclusion remained the
same.
LIMITATIONS
The present study had some limitations. We used
both PET and PET/CT systems. The detector and
method of attenuation correction were not same. How-
ever, the current visual analyses focused on the
existence of diffuse physiological myocardial FDG
uptake. This visual approach was simple and relatively
independent from attenuation correction or other system
specifications. A previous study by Youssef et al
assessed cardiac involvement sarcoidosis using 3 differ-
ent PET scanners from 3 different centers.4 In the
quantitative analysis, each system showed that the
Figure 4. FFA levels for patients with and without diffuse LV
FDG uptake. The group that fasted for longer and had a low-
carbohydrate diet showed higher FFA levels before UFH
injection than did the short-fast group. In the short-fast group,
patients with LV diffuse FDG uptake showed significantly
lower FFA levels than did patients without LV diffuse uptake
before UFH injection. Group A1: patients with minimum 6 h
fasting who showed positive diffuse LV FDG uptake. Group
A2: patients with minimum 6 h fasting who showed negative
diffuse LV FDG uptake. Group B: patients with minimum 18 h
fasting and LCD preparation.
Table 4. Blood sample data for patients with minimum 6 h of fasting
Pre UFH injection Post UFH injection
FPG (mg/dL) IRI (lU/mL) FFA (lEq/L) IRI (lU/mL) FFA (lEq/L)
Group A1 88.3 ± 6.0 4.04 ± 2.53 432.1 ± 296.1 4.46 ± 2.86 1804.2 ± 739.7*
Group A2 95.3 ± 17.2 3.55 ± 3.08 733.7 ± 276.8 4.47 ± 2.21 2110.8 ± 691.5*
P value .052 .23 .0023 .60 .26
Group A1: patients who had positive diffuse LV FDG uptake. Group A2: patients who had negative diffuse LV FDG uptake
UFH, unfractionated heparin; FPG, fasting plasma glucose; IRI, immunoreactive insulin; FFA, free fatty acid; LCD, low-carbohydrate
diet
*P\ .0001 vs before UFH administration (group A1) and negative (group A2)
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cardiac metabolic volume was significantly larger in the
diffuse uptake group. The results were consistent. Thus,
the effects of using different PET systems may have
minimal impact on the current study similar to the
previous study by Youssef et al.
Patients in group A were instructed to fast for a
minimum of 6 h; however, the actual fasting time of
group A was not available. For the patients in group B,
fasting time was based on self-reporting. However, all
patients were admitted to hospital and were provided
dinner at the same time, and therefore, reported fasting
times should be accurate. Obvious whole LV FDG
accumulation higher than liver uptake was defined as
diffuse LV FDG uptake. However, physiological uptake
may sometimes be seen in only part of the LV
myocardium rather than in the whole, and therefore,
further investigation to reveal the relationship between
other patterns of FDG uptake and fasting conditions is
warranted.
Recently, prolonged fasting and diet modifications
including a low-carbohydrate diet and a high-fat diet
have been applied to FDG PET/CT studies in patients
with CS. In the current study, we did not evaluate the
effects of high-fat meals. The effects of adding a high-
fat diet should be studied as the next step.
NEW KNOWLEDGE GAINED
The minimum 18-h fasting with LCD preparation
reduced FPG, increased FFA before UFH administra-
tion, and led to significantly suppressed diffuse LV FDG
uptake in comparison with results of shorter fasting
without LCD protocol. In particular, the FFA level
before UFH injection was significantly lower in patients
with LV diffuse uptake than in patients without LV
diffuse uptake. After the UFH administration, both
groups had significantly increased plasma FFA. How-
ever, the shorter fasting group had a higher frequency of
physiological FDG uptake. Therefore, UFH might not
play a significant role in reducing diffuse LV FDG
uptake. This finding adds new insight over that from
previous studies.
CONCLUSIONS
Fasting for more than 18 h combined with a low-
carbohydrate diet preparation significantly reduced
physiological LV FDG uptake and increased FFA levels
prior to UFH administration in comparison with the case
for shorter fasting preparations. There were no signif-
icant differences in FFA levels after UFH injection
between patients with diffuse LV FDG uptake and
patients without diffuse LV FDG uptake. Therefore, this
protocol of prolonged fasting with a low-carbohydrate
diet preparation may be useful for detecting inflamma-
tory regions of CS in clinical settings.
Acknowledgments
The authors thank Shigeo Oomagari, MSc; Ken-ichi
Nishijima, PhD; Kumi Ajiki; and Eriko Suzuki for their support
for this study. This study was supported in part by grants from
the Ministry of Education, Culture, Sports, Science and
Technology of Japan (Category B, No. 23390294, Category
Young Investigator, No. 23790826), and the Hokkaido Heart
Association for Research (H-23) (Sapporo, Japan).
Dr. Yoshinaga is supported by the Imura Clinical Research
Award (Adult Vascular Disease Research Foundation).
Disclosure
The authors have indicated that they have no financial
conflict of interest.
Open Access
This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any med-
ium, provided you give appropriate credit to the original au-
thor(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made.
References
1. Ishida Y, Yoshinaga K, Miyagawa M, Moroi M, Kondoh C, Kiso
K, et al. Recommendations for F-fluorodeoxyglucose positron
emission tomography imaging for cardiac sarcoidosis: Japanese
Society of Nuclear Cardiology Recommendations. Ann Nucl Med
2014;28:393-403.
2. Ohira H, Tsujino I, Yoshinaga K. (1)(8)F-Fluoro-2-deoxyglucose
positron emission tomography in cardiac sarcoidosis. Eur J Nucl
Med Mol Imaging 2011;38:1773-1783.
3. Schatka I, Bengel FM. Advanced imaging of cardiac sarcoidosis. J
Nucl Med 2014;55:99-106.
4. Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg
G, et al. The use of 18F-FDG PET in the diagnosis of cardiac
sarcoidosis: A systematic review and metaanalysis including the
Ontario experience. J Nucl Med 2012;53:241-248.
5. Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA,
Duvernoy CS, et al. HRS expert consensus statement on the
diagnosis and management of arrhythmias associated with cardiac
sarcoidosis. Heart Rhythm 2014;11:1305-1323.
6. Sudo S, Hattori N, Manabe O, Kato F, Mimura R, Magota K, et al.
FDG PET/CT diagnostic criteria may need adjustment based on
MRI to estimate the presurgical risk of extrapelvic infiltration in
patients with uterine endometrial cancer. Eur J Nucl Med Mol
Imaging 2015;42:676-684.
7. Hirata K, Kobayashi K, Wong KP, Manabe O, Surmak A, Tamaki
N, et al. A semi-automated technique determining the liver stan-
dardized uptake value reference for tumor delineation in FDG
PET-CT. PLoS One 2014;9:e105682.
Journal of Nuclear Cardiology Manabe et al 251
Volume 23, Number 2:244–52 Long fasting & physiological FDG uptake
8. AhmadianA, BroganA, Berman J, SverdlovAL,MercierG,Mazzini
M, et al. Quantitative interpretation of FDGPET/CTwithmyocardial
perfusion imaging increases diagnostic information in the evaluation
of cardiac sarcoidosis. J Nucl Cardiol 2014;21:925-939.
9. Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet
2003;361:1111-1118.
10. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med
1997;336:1224-1234.
11. Camici P, FerranniniE,OpieLH.Myocardialmetabolism in ischemic
heart disease: Basic principles and application to imaging by positron
emission tomography. Prog Cardiovasc Dis 1989;32:217-238.
12. Yoshinaga K, Tamaki N. Imaging myocardial metabolism. Curr
Opin Biotechnol 2007;18:52-59.
13. Langah R, Spicer K, Gebregziabher M, Gordon L. Effectiveness of
prolonged fasting 18f-FDG PET-CT in the detection of cardiac
sarcoidosis. J Nucl Cardiol 2009;16:801-810.
14. Manabe O, Ohira H, Yoshinaga K, Sato T, Klaipetch A, Oyama-
Manabe N, et al. Elevated (18)F-fluorodeoxyglucose uptake in the
interventricular septum is associated with atrioventricular block in
patients with suspected cardiac involvement sarcoidosis. Eur J
Nucl Med Mol Imaging 2013;40:1558-1566.
15. Knuuti MJ, Maki M, Yki-Jarvinen H, Voipio-Pulkki LM, Harkonen
R, HaaparantaM, et al. The effect of insulin and FFA onmyocardial
glucose uptake. J Mol Cell Cardiol 1995;27:1359-1367.
16. Jeong J, Kong E, Chun K, Cho I. The impact of energy substrates,
hormone level and subject-related factors on physiologic
myocardial (18)F-FDG uptake in normal humans. Nucl Med Mol
Imaging 2013;47:225-231.
17. Kreissl MC, Stout DB, Wong KP, Wu HM, Caglayan E, Ladno W,
et al. Influence of dietary state and insulin on myocardial, skeletal
muscle and brain [F]-fluorodeoxyglucose kinetics in mice.
EJNMMI Res 2011;1:8.
18. Osborne MT, Hulten EA, Singh A, Waller AH, Bittencourt MS,
Stewart GC, et al. Reduction in (1)(8)F-fluorodeoxyglucose uptake
on serial cardiac positron emission tomography is associated with
improved left ventricular ejection fraction in patients with cardiac
sarcoidosis. J Nucl Cardiol 2014;21:166-174.
19. Rogers IS, Nasir K, Figueroa AL, Cury RC, Hoffmann U, Ver-
mylen DA, et al. Feasibility of FDG imaging of the coronary
arteries: Comparison between acute coronary syndrome and stable
angina. JACC Cardiovasc Imaging 2010;3:388-397.
20. Wykrzykowska J, Lehman S, Williams G, Parker JA, Palmer MR,
Varkey S, et al. Imaging of inflamed and vulnerable plaque in
coronary arteries with 18F-FDG PET/CT in patients with sup-
pression of myocardial uptake using a low-carbohydrate, high-fat
preparation. J Nucl Med 2009;50:563-568.
21. Ishimaru S, Tsujino I, Takei T, Tsukamoto E, Sakaue S, Kamigaki
M, et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron
emission tomography images indicates cardiac involvement of
sarcoidosis. Eur Heart J 2005;26:1538-1543.
22. Kobayashi Y, Kumita S, Fukushima Y, Ishihara K, Suda M,
Sakurai M. Significant suppression of myocardial (18)F-fluo-
rodeoxyglucose uptake using 24-h carbohydrate restriction and a
low-carbohydrate, high-fat diet. J Cardiol 2013;62:314-319.
23. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to
PERCIST: Evolving considerations for PET response criteria in
solid tumors. J Nucl Med 2009;50:122S-150S.
24. Hiraga HHM, Iwai K. Guidelines for diagnosis of cardiac sar-
coidosis: Study report on diffuse pulmonary diseases (in Japanese).
Tokyo: The Japanese Ministry of Health and Welfare; 1993. p. 23-
24.
25. Taegtmeyer H, Overturf ML. Effects of moderate hypertension on
cardiac function and metabolism in the rabbit. Hypertension
1988;11:416-426.
26. Neely JR, Morgan HE. Relationship between carbohydrate and
lipid metabolism and the energy balance of heart muscle. Annu
Rev Physiol 1974;36:413-459.
27. Romijn JA, Godfried MH, Hommes MJ, Endert E, Sauerwein HP.
Decreased glucose oxidation during short-term starvation. Meta-
bolism 1990;39:525-530.
28. Wisneski JA, Gertz EW, Neese RA, Gruenke LD, Morris DL,
Craig JC. Metabolic fate of extracted glucose in normal human
myocardium. J Clin Invest 1985;76:1819-1827.
29. Ferrannini E, Santoro D, Bonadonna R, Natali A, Parodi O,
Camici PG. Metabolic and hemodynamic effects of insulin on
human hearts. Am J Physiol 1993;264:E308-E315.
30. Morooka M, Moroi M, Uno K, Ito K, Wu J, Nakagawa T, et al.
Long fasting is effective in inhibiting physiological myocardial
18F-FDG uptake and for evaluating active lesions of cardiac sar-
coidosis. EJNMMI Res 2014;4:1.
31. Cheng VY, Slomka PJ, Ahlen M, Thomson LE, Waxman AD,
Berman DS. Impact of carbohydrate restriction with and without
fatty acid loading on myocardial 18F-FDG uptake during PET: A
randomized controlled trial. J Nucl Cardiol 2010;17:286-291.
32. Kumar P, Patel CD, Singla S, Malhotra A. Effect of duration of
fasting and diet on the myocardial uptake of F-18-2-fluoro-2-
deoxyglucose (F-18 FDG) at rest. Indian J Nucl Med 2014;29:140-
145.
33. Ito K, Morooka M, Okazaki O, Minaminoto R, Kubota K, Hiroe
M. Efficacy of heparin loading during an 18F-FDG PET/CT
examination to search for cardiac sarcoidosis activity. Clin Nucl
Med 2013;38:128-130.
34. Wisneski JA, Gertz EW, Neese RA, Mayr M. Myocardial meta-
bolism of free fatty acids. Studies with 14C-labeled substrates in
humans. J Clin Invest 1987;79:359-366.
35. Persson E. Lipoprotein lipase, hepatic lipase and plasma lipolytic
activity. Effects of heparin and a low molecular weight heparin
fragment (Fragmin). Acta Med Scand Suppl 1988;724:1-56.
36. Gormsen LC, Christensen NL, Bendstrup E, Tolbod LP, Nielsen
SS. Complete somatostatin-induced insulin suppression combined
with heparin loading does not significantly suppress myocardial
18F-FDG uptake in patients with suspected cardiac sarcoidosis. J
Nucl Cardiol 2013;20:1108-1115.
37. Ozguven MA, Karacalioglu AO, Ince S, Emer MO. Altered
biodistribution of FDG in patients with type-2 diabetes mellitus.
Ann Nucl Med 2014;28:505-511.
252 Manabe et al Journal of Nuclear Cardiology
Long fasting & physiological FDG uptake March/April 2016
